Journal article · 2025 · Open access

Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database

Hotaka Maruyama, Eiko Iwasa, Shizuhiko Watanabe, Tomoaki Hasegawa, Kazuhiro Kajiyama, Taihei Tanaka

Clinical Pharmacology & Therapeutics, 119(3), 721–728 · Published 21 November 2025 · DOI 10.1002/cpt.70142

Open PDFView at the publisherCite this paper

In brief

“Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database” is a 2025 journal article by Hotaka Maruyama and 5 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 11 citations as of 17 November 2026, which puts it in the top 2% of works published in 2025 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Clinical Pharmacology & Therapeutics.

Citations
11
Most cited in
2026 (11)
Field-weighted impact
7.74
References
21
Authors
6

Abstract

Disproportionality analyses suggested a cardiovascular risk signal for romosozumab, while statistically significant associations were not found in the real‐world database studies. Therefore, a larger comparative study was necessary to examine this signal. This study aimed to compare the cardiovascular risks of romosozumab with those of teriparatide in the overall population and in groups with a history of major adverse cardiovascular events (MACE). A new user cohort study was conducted using Japan’s national claims database. Patients aged ≥ 40 years who initiated romosozumab or teriparatide between March 2019 and March 2023 were analyzed. A multivariable Cox proportional hazards model was used to estimate the adjusted hazard ratio (aHR) for MACE. Subgroup analyses were conducted based on MACE history. A total of 251,219 romosozumab and 500,445 teriparatide users were analyzed (most common age group was 80–89 years for both drugs; men: 9.33% for romosozumab and 14.14% for teriparatide). MACE occurred in 1853 romosozumab and 3427 teriparatide users, with incidence rates of 1.09 and 1.22 per 100 person‐years, respectively. The aHR (95% confidence interval [CI]) for romosozumab compared with teriparatide was 1.00 (0.94–1.06). In subgroup analyses based on MACE history, the aHRs (95% CI) for no history, for the one‐year period leading up to t 0 , and for more than 1 year before t 0 were 1.01 (0.95–1.08), 0.93 (0.72–1.21), and 1.00 (0.85–1.18), respectively. In conclusion, no statistically significant difference in MACE risk was observed between romosozumab and teriparatide in Japan’s national claims database, regardless of MACE history.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Maruyama, H., Iwasa, E., Watanabe, S., Hasegawa, T., Kajiyama, K., & Tanaka, T. (2025). Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database. Clinical Pharmacology & Therapeutics, 119(3), 721–728. https://doi.org/10.1002/cpt.70142

MLA 9

Maruyama, Hotaka, et al. “Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database.” Clinical Pharmacology & Therapeutics, vol. 119, no. 3, 2025, pp. 721–728. https://doi.org/10.1002/cpt.70142.

Chicago

Maruyama, Hotaka, Eiko Iwasa, Shizuhiko Watanabe, Tomoaki Hasegawa, Kazuhiro Kajiyama, and Taihei Tanaka. 2025. “Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database.” Clinical Pharmacology & Therapeutics 119 (3): 721–728. https://doi.org/10.1002/cpt.70142.

Harvard

Maruyama, H. et al. (2025) ‘Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database’, Clinical Pharmacology & Therapeutics, 119(3), pp. 721–728. doi:10.1002/cpt.70142.

IEEE

H. Maruyama, E. Iwasa, S. Watanabe, T. Hasegawa, K. Kajiyama, and T. Tanaka, “Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database,” Clinical Pharmacology & Therapeutics, vol. 119, no. 3, pp. 721–728, 2025, doi: 10.1002/cpt.70142.

BibTeX

@article{maruyama2025cardiovascular,
  title     = {{Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database}},
  author    = {Maruyama, Hotaka and Iwasa, Eiko and Watanabe, Shizuhiko and Hasegawa, Tomoaki and Kajiyama, Kazuhiro and Tanaka, Taihei},
  journal   = {Clinical Pharmacology \& Therapeutics},
  year      = {2025},
  volume    = {119},
  number    = {3},
  pages     = {721--728},
  doi       = {10.1002/cpt.70142},
  url       = {https://doi.org/10.1002/cpt.70142}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research

  • romosozumab
  • teriparatide
  • cardiovascular risk
  • major adverse cardiovascular events
  • osteoporosis
  • drug safety
  • new-user cohort

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Maruyama, H., Iwasa, E., Watanabe, S., Hasegawa, T., Kajiyama, K., & Tanaka, T. (2025). Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database. Clinical Pharmacology & Therapeutics, 119(3), 721–728. https://doi.org/10.1002/cpt.70142

How many times has this paper been cited?

11 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.

Who wrote this paper?

Hotaka Maruyama, Eiko Iwasa, Shizuhiko Watanabe, Tomoaki Hasegawa, Kazuhiro Kajiyama, Taihei Tanaka.

What is the DOI of this paper?

10.1002/cpt.70142, permanently at https://doi.org/10.1002/cpt.70142. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.